STAT+: PepGen says early trial for muscular dystrophy drug looks promising
The biotech PepGen said Tuesday that its experimental drug had shown, by one key measure, the most promising early data yet in the race to treat a muscle disorder that affects over 100,000 people in the U.S.
Key points
- Dyne Therapeutics is close to completing a pivotal trial for a DM1 drug.
- Continue to STAT+ to read the full story….
- Tuesday’s data come from six patients, who were treated for 12 weeks.
Novartis just announced that a DM1 drug it acquired in its $12 billion buyout of Avidity Biosciences failed to improve a key measure of muscle control in a Phase 3 trial, casting a pall over the field.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.